drugset / Trial / NCT05327595
A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)
RandomizedSequentialDouble-blindTreatment
Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in participants with T2DM. Blood tests will be done to check how much LY3549492 gets into the bloodstream and how the body handles LY3549492. This study has two parts. Each participant will enroll in only one part. The study will last either 12 or 13 weeks, depending on part.
Timeline
- Start
- 2022-05-09
- Primary completion
- 2024-04-22
- Completion
- 2024-04-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY3549492 | Unknown | — | Oral |
| Background | Atorvastatin | Small molecule | — | Oral |
| Background | Midazolam | Small molecule | — | Oral |